(ChemotherapyAdvisor) – Cardiovascular co-morbidity is associated with increased treatment regret among men with recurrent prostate cancer, according to a team of US-based researchers. The conclusion is based on a study of the same name, which was published in the July issue of the British Journal of Urology International.

In this study, the investigators aimed to determine whether cardiovascular co-morbidity is associated with increased treatment regret among men with recurrent prostate cancer. To make this determination, the investigators analyzed a study cohort of 795 men in the Comprehensive, Observational, Multi-center, Prostate Adenocarcinoma (COMPARE) registry who had experienced biochemical recurrence at a median of 5.5 years after prostatectomy, external beam radiation therapy, brachytherapy, or primary androgen deprivation therapy.

“Cardiovascular co-morbidity, which included myocardial infarction, congestive heart failure, angina, diabetes, stroke or circulation problems, was defined using a validated two-question screening process after adjusting for sociodemographic and treatment factors and post-treatment bladder and bowel toxicity,” the investigators wrote.

Continue Reading

It was reported that 14.8% of the 795 evaluable men reported regret. Factors associated with increased treatment regret included cardiovascular co-morbidity (adjusted odds ratio [AOR]= 1.52 [95% CI:1.00–2.31], P=0.048); younger age (AOR: 0.97 [95% CI 0.94–0.99] per year increase in age, P=0.019); and bowel toxicity after treatment (AOR 1.58 [95% CI 1.03–2.43], P=0.038).

Based on the results of this study, the investigators concluded: “Among men with recurrent prostate cancer, those with cardiovascular co-morbidity were >50% more likely to experience treatment regret than men without cardiovascular co-morbidity. These data provide a rationale for men with cardiovascular co-morbidity to give additional consideration to active surveillance for their newly diagnosed prostate cancer.”